Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.